Sandostatin

In some countries, this medicine may only be approved for veterinary use.

In the US, Sandostatin (octreotide systemic) is a member of the drug class somatostatin and somatostatin analogs and is used to treat Acromegaly, Carcinoid Tumor, Diabetes - Type 1, Diarrhea, Gastrinoma, Glucagonoma, Insulinoma, Pituitary Adenoma, Small Bowel or Pancreatic Fistula and Vasoactive Intestinal Peptide Tumor.

US matches:

• Sandostatin


• Sandostatin LAR Depot Kit


• Sandostatin LAR Depot injectable


• Sandostatin injectable


• Sandostatin LAR Depot


• Sandostatin LAR

UK matches:

• Sandostatin Ampoules and Multidose vial
• Sandostatin 0.05mg/ml, 0.1 mg/ml, 0.5 mg/ml Ampoules and Multidose Vial 1 mg/5 ml (SPC)
• Sandostatin LAR (SPC)

Ingredient matches for Sandostatin

Octreotide

Octreotide is reported as an ingredient of Sandostatin in the following countries:

• Argentina


• Austria


• Bosnia & Herzegowina


• Bulgaria


• Chile


• Czech Republic


• Denmark


• Greece


• Hong Kong


• Iceland


• India


• Indonesia


• Ireland


• Israel


• Latvia


• Luxembourg


• Malta


• New Zealand


• Norway


• Peru


• Romania


• Russian Federation


• Serbia


• South Africa


• Spain


• Taiwan


• Thailand


• Turkey


• United Kingdom


• Venezuela


• Vietnam

Octreotide acetate (a derivative of Octreotide) is reported as an ingredient of Sandostatin in the following countries:

• Australia


• Canada


• China


• Croatia (Hrvatska)


• Estonia


• Finland


• Georgia


• Germany


• Hungary


• Ireland


• Japan


• Lithuania


• Malaysia


• Oman


• Philippines


• Poland


• Serbia


• Slovakia


• Slovenia


• Sri Lanka


• Sweden


• Switzerland


• United Kingdom


• United States

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.